Covid vaccine: Bharat Biotech's Covaxin reach Ahmedabad for phase-3 trials

The Sola civil hospital is one of the 130 centres across the country where the third phase of clinical trials of Covaxin would be conducted

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Press Trust of India Ahmedabad
1 min read Last Updated : Nov 24 2020 | 10:19 PM IST

A consignment of Covaxin, one

of the COVID-19 vaccine candidates, reached Sola civil hospital here in Gujarat on Tuesday for the phase-III clinical trials, a senior official said.

The Sola civil hospital is one of the 130 centres across the country where the third phase of clinical trials of Covaxin would be conducted, said H G Koshia, Commissioner, Gujarat Food and Drug Control Administration (FDCA).

"Covaxin is being developed indigenously by vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR)," Koshia told reporters.

While authorities at the civil hospital remain tight-lipped, Ahmedabad-West MP Kirit Solanki tweeted a photo of "Covaxin trial room" at the hospital.

"Corona's trial vaccine has arrived at Sola Civil. Trial will commence on 1,000 volunteers starting Friday. Sola Civil has formed a team to check the effects of the vaccine. The hospital has also formed one Ethical Committee and a Scientific Committee for supervision of trials," Solanki tweeted.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineBharat BiotechGujarat

First Published: Nov 24 2020 | 10:09 PM IST

Next Story